Boehringer Ingelheim Acquires Evax AG to Expand Equine Health Pipeline

Founded more than a decade ago at the University of Zurich, Evax has been developing therapeutic vaccines that use virus-like particle technology to target the underlying causes of allergic diseases.

Boehringer Ingelheim has acquired Swiss biotechnology company Evax AG to expand its equine health pipeline, with a focus on therapeutic vaccines for allergic skin diseases and other areas of unmet need in horses.

Founded more than a decade ago at the University of Zurich, Evax has been developing therapeutic vaccines that use virus-like particle technology to target the underlying causes of allergic diseases. The acquisition brings Evax’s technology and expertise into Boehringer Ingelheim Animal Health.

Allergies and dermatologic conditions are common in horses and can significantly affect their health and well-being. Existing management options, including shampoos and topical treatments, can require frequent use and often provide temporary relief, while some therapies, such as corticosteroids, can present safety concerns.

Evax’s therapeutic vaccine approach is designed to stimulate the horse’s immune system to produce neutralizing antibodies against disease-related targets. The technology is being developed with the potential to provide longer-lasting treatment compared with some existing management approaches.

“We’re excited to have the potential to offer horse owners the first innovative therapeutic option for allergic skin diseases targeting the underlying cause of the disease,” said Saskia Kley, Global Head of Equine at Boehringer Ingelheim. She added that the approach could potentially support longer duration of action, treatment outcomes and convenience.

Evax CEO and Founder Dr. Antonia Gabriel said the company would leverage Boehringer Ingelheim’s innovation, supply and commercial capabilities as the technology advances through further development.

The acquisition also builds on Boehringer Ingelheim’s existing work in therapeutic vaccines. The company previously collaborated with and subsequently acquired Saiba Animal Health in 2024.

According to Knut Elbers, Head of Global Innovation, Animal Health at Boehringer Ingelheim, virus-like particle technology could have applications across animal health, including chronic diseases in pets and allergy-related disorders in horses.

Financial terms of the transaction were not disclosed.

Stay tuned for more such updates on Digital Health News